论文部分内容阅读
加《医学邮报》第16卷第1期(1980年)报道阿纳海姆消息:Amrinone是一种新的、促进心肌收缩的强效药物,可对抗左心室衰竭,对于已服用其他强心药如洋地黄而无效的充血性心力衰竭病人,Amrinone也有作用。在美国心脏病学会的年会上,5组研究人员讨论了此药用于实验动物和人的经验,但此药仍属实验性药物。至今,Amrinone在美国已用其治疗了89例病人。辛辛那提大学药理学和细胞生物生理学系的施瓦茨(Arnold Schwartz)说,Amrinone是独特的、正性促收缩能的强心剂,对于正常和衰竭的心脏均有类似洋地黄的作用。他在狗
Plus Medical Journal Volume 16, Number 1 (1980) Anaheim News: Amrinone is a new, potent drug that boosts myocardial contractions against left ventricular failure. For those who have taken other cardiac Amrinone also has a role in patients with congestive heart failure, such as digitalis, which is not effective. At the annual meeting of the American College of Cardiology, five groups of researchers discussed the experience of using the drug in laboratory animals and humans, but the drug is still experimental. To date, Amrinone has treated 89 patients in the United States. Arnold Schwartz, of the Department of Pharmacology and Cell Biophysiology at the University of Cincinnati, says Amrinone is a unique, positive, contractile and cardiotonic agent that acts like digitalis on both normal and failing hearts. He is a dog